Arkolith/Insider Trading/MREO/Form 4

Scots-Knight Denise

Chief Executive Officer, DirectorMereo BioPharma Group plc (MREO) · full profile →Form 4 · filed Feb 2, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
0 non-derivative · 3 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2026Grant(A)345K—$0345K
Feb 1, 2026Grant(A)1.0M—$01.0M
Feb 1, 2026Grant(A)480K—$0480K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-033751) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML